STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVCT
  4. [EFFECT] Nuvectis Pharma, Inc. SEC Filing

[EFFECT] Nuvectis Pharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: February 20, 2026 4:30 P.M.
Form: S-3
CIK: 0001875558
Company Name: Nuvectis Pharma, Inc.
File Number: 333-293459

Source: View Original Filing on SEC EDGAR

Stock NVCT logo
Nuvectis Pharma, Inc.

NASDAQ:NVCT

NVCT Rankings

#4378 Ranked by Market Cap
N/A Ranked by Dividends

NVCT Latest News

Feb 11, 2026
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Dec 17, 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Nov 25, 2025
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Nov 4, 2025
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Nov 4, 2025
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

NVCT Latest SEC Filings

Feb 13, 2026
[S-3] Nuvectis Pharma, Inc. Shelf Registration Statement
Feb 11, 2026
[8-K] Nuvectis Pharma, Inc. Reports Material Event
Feb 11, 2026
[10-K] Nuvectis Pharma, Inc. Files Annual Report
Jan 9, 2026
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity
Jan 9, 2026
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity

NVCT Stock Data

225.44M
15.47M
Biotechnology
Pharmaceutical Preparations
Link
United States
FORT LEE